Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA CAR-NK
- Development stage
- Unknown
- Lead developer
- Shenzhen Puruijin Biological Pharmaceutical
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA CAR-NK (PRG-NK01) is an allogeneic, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Shenzhen Pregene Biopharma for the treatment of relapsed/refractory multiple myeloma. The therapy consists of NK cells derived from healthy donor peripheral blood, genetically engineered via lentiviral transduction to express a CAR targeting B-cell maturation antigen (BCMA). The specific construct utilizes a single-domain antibody (VHH/nanobody) for BCMA recognition, a CD28 costimulatory domain, and ectopic expression of interleukin-15 (IL-15) to promote NK cell persistence and anti-tumor activity. By using NK cells instead of T cells, the therapy aims to reduce the risk of cytokine release syndrome (CRS) and graft-versus-host disease (GvHD) while providing a more accessible treatment option.
- Other names
- BCMA-CD28-IL15 CAR-NKBCMA-CD-28-IL15 CAR-NKBCMA-CD 28-IL15 CAR-NKChimeric Antigen Receptor NK Cell Injection Targeting BCMA
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA CAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA CAR-NK.